15. July 2026 – 17. July 2026
At the conference, our team contributed to the discussion by presenting research that explores the societal, economic, and fiscal impacts of healthcare innovations beyond traditional clinical outcomes.
Jasper Ubels presented WifOR’s latest research on “The Socioeconomic Impact of Pneumococcal Vaccination on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Switzerland.” The findings highlight how increasing vaccination coverage among COPD patients could generate substantial health and societal benefits, including fewer hospitalizations and productivity gains exceeding €12 billion.
In the session “From Health to Wealth: Fiscal Impact of Vorasidenib in IDH-mutant Grade 2 Glioma in Germany,” Trust Muchadeyi explored the financial benefits of delaying disease progression with preliminary findings indicating significant healthcare savings and fiscal revenues preserved.
Shimona Seth shared findings from “Societal Impact of Vorasidenib in IDH-mutant Grade 2 Glioma in Germany,” quantifying the broader socioeconomic benefits of delaying disease progression with preliminary findings indicating considerable contribution of unpaid work, which is often neglected in conventional cost-effectiveness analysis.
By capturing impacts on productivity, public finances, and broader societal outcomes, health economic research can help decision-makers better understand the full value that health interventions create.